Motley Fool Asset Management LLC Has $3.04 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Motley Fool Asset Management LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,509 shares of the biopharmaceutical company’s stock after acquiring an additional 2,135 shares during the period. Motley Fool Asset Management LLC’s holdings in Gilead Sciences were worth $3,039,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Strategic Blueprint LLC lifted its stake in Gilead Sciences by 8.1% in the 3rd quarter. Strategic Blueprint LLC now owns 4,388 shares of the biopharmaceutical company’s stock valued at $329,000 after purchasing an additional 328 shares during the last quarter. Proficio Capital Partners LLC bought a new position in Gilead Sciences in the 3rd quarter valued at approximately $207,000. Koshinski Asset Management Inc. raised its stake in shares of Gilead Sciences by 5.1% during the third quarter. Koshinski Asset Management Inc. now owns 2,975 shares of the biopharmaceutical company’s stock valued at $223,000 after acquiring an additional 145 shares during the last quarter. DeDora Capital Inc. raised its stake in shares of Gilead Sciences by 13.1% during the third quarter. DeDora Capital Inc. now owns 10,114 shares of the biopharmaceutical company’s stock valued at $758,000 after acquiring an additional 1,170 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC raised its stake in shares of Gilead Sciences by 11.9% during the third quarter. Measured Wealth Private Client Group LLC now owns 13,931 shares of the biopharmaceutical company’s stock valued at $1,044,000 after acquiring an additional 1,478 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on GILD shares. Royal Bank of Canada dropped their price target on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 14th. Oppenheimer reiterated an “outperform” rating and set a $105.00 price objective on shares of Gilead Sciences in a research report on Friday, April 19th. StockNews.com cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 19th. Wells Fargo & Company reduced their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. Finally, Barclays reduced their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, February 12th. Ten equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Hold” and a consensus target price of $84.57.

Gilead Sciences Stock Down 2.7 %

Shares of GILD traded down $1.81 during trading hours on Thursday, reaching $65.27. 15,163,484 shares of the stock traded hands, compared to its average volume of 7,415,576. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The stock has a fifty day simple moving average of $71.40 and a 200 day simple moving average of $76.32. Gilead Sciences, Inc. has a 52 week low of $65.09 and a 52 week high of $87.86. The company has a market cap of $81.27 billion, a price-to-earnings ratio of 14.50, a PEG ratio of 0.96 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the firm earned $1.37 earnings per share. On average, equities analysts forecast that Gilead Sciences, Inc. will post 5.24 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were given a $0.77 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $3.08 annualized dividend and a yield of 4.72%. Gilead Sciences’s payout ratio is currently 68.44%.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.